Orexigen Pharmaceuticals Inc., of San Diego, issued a statement relating to the acquisition of full U.S. rights to Contrave (naltrexone HCl / bupropion HCl extended release) from Osaka, Japan-based Takeda Pharmaceutical Co. Ltd. Transfer of the recently initiated multiyear Convene trial involves substantial complexity due to the scope, size and nature of the study, the company said.